➡️𝐅𝐫𝐨𝐦 𝐇𝐄𝐋𝐈𝐎𝐒-𝐁. 𝐓𝐨 𝐀𝐂𝐀𝐂𝐈𝐀-𝐇𝐂𝐌. 𝐍𝐨𝐰 𝐂𝐀𝐑𝐃𝐈𝐎-𝐓𝐓𝐑𝐚𝐧𝐬𝐟𝐨𝐫𝐦.
Us2.ai’s software has now supported echocardiographic core lab analysis across three major Phase 3 cardiology trials, spanning transthyretin amyloidosis (ATTR-CM) and hypertrophic cardiomyopathy.
The latest, CARDIO-TTRansform, is the largest clinical trial in ATTR cardiomyopathy to date, with echo analysis across more than 1,400 patients, published in Circulation.
Core lab analysis is where echo measurement is held to a high standard: independent, blinded and consistent across every site in a trial. In each of these three trials, our software was used to support that analysis.
𝐋𝐨𝐨𝐤𝐢𝐧𝐠 𝐟𝐨𝐫 𝐚𝐧 𝐀𝐈 𝐞𝐜𝐡𝐨 𝐬𝐨𝐥𝐮𝐭𝐢𝐨𝐧 𝐭𝐨 𝐬𝐮𝐩𝐩𝐨𝐫𝐭 𝐲𝐨𝐮𝐫 𝐜𝐨𝐫𝐞 𝐥𝐚𝐛? 𝐋𝐞𝐭’𝐬 𝐭𝐚𝐥𝐤 → us2.ai
📖 𝐑𝐞𝐚𝐝 𝐦𝐨𝐫𝐞 → us2.ai/news/ai-assist…
Us2.ai’s software has now supported echocardiographic core lab analysis across three major Phase 3 cardiology trials, spanning transthyretin amyloidosis (ATTR-CM) and hypertrophic cardiomyopathy.
The latest, CARDIO-TTRansform, is the largest clinical trial in ATTR cardiomyopathy to date, with echo analysis across more than 1,400 patients, published in Circulation.
Core lab analysis is where echo measurement is held to a high standard: independent, blinded and consistent across every site in a trial. In each of these three trials, our software was used to support that analysis.
𝐋𝐨𝐨𝐤𝐢𝐧𝐠 𝐟𝐨𝐫 𝐚𝐧 𝐀𝐈 𝐞𝐜𝐡𝐨 𝐬𝐨𝐥𝐮𝐭𝐢𝐨𝐧 𝐭𝐨 𝐬𝐮𝐩𝐩𝐨𝐫𝐭 𝐲𝐨𝐮𝐫 𝐜𝐨𝐫𝐞 𝐥𝐚𝐛? 𝐋𝐞𝐭’𝐬 𝐭𝐚𝐥𝐤 → us2.ai
📖 𝐑𝐞𝐚𝐝 𝐦𝐨𝐫𝐞 → us2.ai/news/ai-assist…